Pharmacoeconomics

Papers
(The H4-Index of Pharmacoeconomics is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Towards Transparency in the Selection of Published Health Utility Inputs in Cost-Utility Analyses: The Health Utility Application Tool (HAT)534
Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?199
Authors’ Reply to Comment on “Risk-Adjusted Performance Measures”86
Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling82
The Impact of Tocilizumab Coverage on Health Equity for Inpatients with COVID-19 in the USA: A Distributional Cost-Effectiveness Analysis81
The Value of Flexible Vaccine Manufacturing Capacity: Value Drivers, Estimation Methods, and Approaches to Value Recognition in Health Technology Assessment80
Value of Innovative Multiple Myeloma Treatments from Patient and Healthcare Provider Perspectives: Evidence from a Discrete Choice Experiment59
Correction to: Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment52
Public Preferences for a COVID-19 Vaccination Program in Quebec: A Discrete Choice Experiment47
Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting43
Meeting the Challenges of Preference-Weighted Health-Related Quality-of-Life Measurement in Children39
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy38
Economic Burden Associated with Pulmonary Arterial Hypertension in the United States36
Advancing Methods to Measure and Reward Healthcare Innovation36
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation33
Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA31
Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies31
Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review28
Impact of Influenza and Influenza-Like Illness on Work Productivity Outcomes: A Systematic Literature Review27
Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy27
The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned26
Systematic Literature Review to Assess Economic Evaluations in Spinal Muscular Atrophy (SMA)26
The Relevance of Including Future Healthcare Costs in Cost-Effectiveness Threshold Calculations for the UK NHS25
EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions24
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment24
Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling24
Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition24
Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based 24
Under-reporting of Validation Efforts for Health Economic Models Persists Despite the Availability of Validation Tools: A Systematic Review24
0.065109968185425